The US scientific journal recognizes the merits of the Cuban anti-covid vaccine



[ad_1]

US magazine BioWorld today highlighted Cuba’s achievements in developing its second candidate Sovereign 02 vaccine against Covid-19, which is currently in Phase I clinical trials. According to the text published in the last few hours, the Caribbean island has a lot of experience in the formulation of conjugate vaccines, a group to which this drug belongs.

“Evidence of this is injectable QUIMI-HIB against Haemophilus Influenzae type B, which causes meningitis and pneumonia in the first years of life,” the text refers.

As Fabrizio Chiodo, a researcher at the Italian National Research Institute, explained to BioWorld, this is the second vaccine under development in the small country of just over 11 million inhabitants and it is “extremely new.

Sovereign 02 consists of a subunit vaccine in which the virus antigen, the receptor binding domain (RBD), is chemically bound to the tetanus toxoid.

This means that the vaccine antigen is a copy molecule of that present in the virus and to obtain it it is necessary to have the genetic information of this viral protein, and by a process of genetic engineering, it is programmed into a cell of the higher organism called CHO.

With these characteristics Soberana 02 gives more hope, for its safety to children, infants and the elderly because it strengthens the immune system, said Chiodo.

Phase I clinical trials of the second largest candidate vaccine in the Antilles against Covid-19 began earlier this month and a group of 40 volunteers aged 19 to 59 have already been vaccinated.

‘This isn’t phase after phase, there is a lot of overlap, so things can go faster. There are ways to let all enforcement agencies know that the situation is very safe with Sovereign 02, ‘the professor told BioWorld.

The Caribbean nation was the first in Latin America to register its own Covid-19 vaccine candidate and currently has four projects for this purpose: Sovereign 01, 02; Mambisa and Abdala.

The president of the BioCubaFarma corporate group, Eduardo Martínez, recently highlighted the strategy outlined for having Cuban vaccines against Covid-19. “It is going well and in 2021 the country’s population will be immunized against this virus,” he said. / Latin Press

[ad_2]
Source link